AR061111A1 - ISOINDOL DERIVATIVES USEFUL TO TREAT PAIN, GASTROINTESTINAL DISORDERS AND CANCER - Google Patents
ISOINDOL DERIVATIVES USEFUL TO TREAT PAIN, GASTROINTESTINAL DISORDERS AND CANCERInfo
- Publication number
- AR061111A1 AR061111A1 ARP070102233A ARP070102233A AR061111A1 AR 061111 A1 AR061111 A1 AR 061111A1 AR P070102233 A ARP070102233 A AR P070102233A AR P070102233 A ARP070102233 A AR P070102233A AR 061111 A1 AR061111 A1 AR 061111A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- amino
- alkoxy
- halogenated
- heteroaryl
- Prior art date
Links
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical class C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 title 1
- 208000018522 Gastrointestinal disease Diseases 0.000 title 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 13
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 10
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 2
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- -1 cyano, amino, acetylamino, acetoxy hydroxyl Chemical group 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000006720 (C1-C6) alkyl (C6-C10) aryl group Chemical group 0.000 abstract 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 1
- JAMULYFATHSZJM-UHFFFAOYSA-N 8-(4-dibenzothiophenyl)-2-(4-morpholinyl)-1-benzopyran-4-one Chemical compound O1C2=C(C=3C=4SC5=CC=CC=C5C=4C=CC=3)C=CC=C2C(=O)C=C1N1CCOCC1 JAMULYFATHSZJM-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Composiciones farmacéuticas, usos y proceso de obtencion. Son utiles en terapia, en particular en el manejo del dolor. Reivindicacion 1: Un compuesto de formula 1, una sal del mismo aceptable para uso farmacéutico, un diastereomero, un enantiomero, o una mezcla de los mismos: donde R1 se selecciona independientemente entre hidrogeno, halogeno, ciano, amino, acetilamino, acetoxi hidroxilo, alcoxi C1-6, hidroxi- alcoxi C1-6, benciloxi-OCH2-C(=O)-R4, -OS(=O)2R4, alquilo C1-6, alcoxi C1-6 halogenado, alquileno C2-6, alquilo C1-6 halogenado, alquenilo C2-6 halogenado, alquilamino C1-6, di-alquil C1-6-amino y amino; R2 se selecciona entre los compuestos de formulas (2) donde dicho grupo utilizado para definir R2 están opcionalmente sustituidos con uno o más grupos seleccionados entre halogeno, alquilo C1-6 halogenado, alquilo C1-6, alcoxi C1-6 halogenado, ciano, nitro, alcoxi C1-6, hidroxi, hidroxi-alquilo C1-6, amino, alquil C1-6arilo-C6-10, alcoxi C1-6-alquilo C1-6, alquil C1-6-carbonilo, alcoxi C1-6-carbonilo, alquil C1-6-amino, di-alquil C1-6-amino, di-alquil C1-6-amino- alquilo C1-6, amino-alquilo C1-6, alquil C1-6-amino-carbonilo, heteroaril C2-5-carbonilo, heterocicloalquil C2-5-carbonilo, aril C6-10-carbonilo, heterocicloalquilo C2-5, cicloalquilo C3-6, cicloalquil C3-6-alquilo C1-6, heteroarilo C2-5, heteroaril C2-5- alquilo C1-6, arilo C6-10 y aril C6-10-alquilo C1-6; R3 se selecciona entre alquilo C1-6, alquenilo C2-6, cicloalquilo C3-6, cicloalquenilo C4-6, alcoxi C1-6, y heterocicloalquilo C2-5; donde dicho alquilo C1-6, alquenilo C2-6, cicloalquilo C3-6, cicloalquenilo C4-65, alcoxi C1-6, y heterocicloalquilo C2-5 utilizado para definir R3 están opcionalmente sustituidos con uno o más grupos seleccionados entre halogeno, alquilo C1-6 halogenado, alquilo C1-6, alcoxi C1-6 halogenado, ciano, nitro, alcoxi C1-6, hidroxi, hidroxi-alquilo C1-6, amino, alquil C1-6-arilo C6-10, alcoxi C1-6-alquilo C1-6, alquil C1-6-carbonilo, alcoxi C1-6- carbonilo, alquil C1-6-amino, di-alquil C1-6-amino, di-alquil C1-6-amino-alquilo C1-6, amino-alquilo C1-6, alquil C1-6-amino-carbonilo, heteroaril C2-5-carbonilo, heterociclo C2-5 alquil-carbonilo, aril C6-10-carbonilo, heterociclo-alquilo C2-5, cicloalquilo C3-6, cicloalquil C3-6-alquilo C1-6, heteroarilo C2-5, heteroaril C2-5-alquilo C1-6, arilo C6-10 y aril C6-10-alquilo C1-6; R4 se selecciona entre alquilo C1-6, alquilo C1-6 halogenado, hidroxi, hidroxialquil C1-6-amino, amino, alcoxi C1-6, alquil C1-6-amino, di-alquil C1-6-amino, hidroxiamino, alcoxi C1-6-amino, bencilamino, heterociclo C2-5-alquilo, heteroarilo C2-5 y heteroaril C2-5-alquilo C1-6; X se selecciona entre -C(=O)- y -CH2-; y m y n se seleccionan independientemente entre 0, 1, 2, 3, 4 y 5, con la condicion de que R3 no sea un 2,6-dioxopiperidin-3-ilo opcionalmente sustituido.Pharmaceutical compositions, uses and process of obtaining. They are useful in therapy, particularly in pain management. Claim 1: A compound of formula 1, a salt thereof acceptable for pharmaceutical use, a diastereomer, an enantiomer, or a mixture thereof: wherein R1 is independently selected from hydrogen, halogen, cyano, amino, acetylamino, acetoxy hydroxyl, C1-6 alkoxy, hydroxy- C1-6 alkoxy, benzyloxy-OCH2-C (= O) -R4, -OS (= O) 2R4, C1-6 alkyl, halogenated C1-6 alkoxy, C2-6 alkylene, C1 alkyl -6 halogenated, halogenated C2-6 alkenyl, C1-6 alkylamino, di- C1-6 alkyl amino and amino; R2 is selected from the compounds of formulas (2) where said group used to define R2 are optionally substituted with one or more groups selected from halogen, halogenated C1-6 alkyl, C1-6 alkyl, halogenated C1-6 alkoxy, cyano, nitro , C1-6 alkoxy, hydroxy, hydroxy C1-6 alkyl, amino, C1-6 alkyl-C6-10 alkyl, C1-6 alkoxy-C1-6 alkyl, C1-6 alkylcarbonyl, C1-6 alkoxycarbonyl, C1-6-amino alkyl, di-C1-6-alkyl-amino, di-C1-6-alkyl-amino-C1-6 alkyl, amino-C1-6 alkyl, C1-6-alkyl-aminocarbonyl, C2-5 heteroaryl -carbonyl, C2-5 heterocycloalkylcarbonyl, C6-10 -carbonyl, C2-5 heterocycloalkyl, C3-6 cycloalkyl, C3-6 cycloalkyl-C1-6 alkyl, C2-5 heteroaryl, C2-5 heteroaryl- C1- 6, C6-10 aryl and C6-10 aryl-C1-6 alkyl; R3 is selected from C1-6 alkyl, C2-6 alkenyl, C3-6 cycloalkyl, C4-6 cycloalkenyl, C1-6 alkoxy, and C2-5 heterocycloalkyl; wherein said C1-6 alkyl, C2-6 alkenyl, C3-6 cycloalkyl, C4-65 cycloalkenyl, C1-6 alkoxy, and C2-5 heterocycloalkyl used to define R3 are optionally substituted with one or more groups selected from halogen, C1 alkyl -6 halogenated, C1-6 alkyl, halogenated C1-6 alkoxy, cyano, nitro, C1-6 alkoxy, hydroxy, hydroxy C1-6 alkyl, amino, C1-6 alkyl-C6-10 aryl, C1-6 alkoxy C 1-6 alkyl, C 1-6 alkylcarbonyl, C 1-6 alkoxycarbonyl, C 1-6 alkyl, amino C 1-6 alkyl, diC 1-6 alkyl aminoC 1-6 alkyl, amino -C 1-6 alkyl, C 1-6 alkyl aminocarbonyl, C2-5 heteroaryl carbonyl, C2-5 heterocycle alkylcarbonyl, C6-10 arylcarbonyl, heterocycle C2-5 alkyl, C3-6 cycloalkyl, cycloalkyl C3-6-C1-6 alkyl, C2-5 heteroaryl, C2-5 heteroaryl-C1-6 alkyl, C6-10 aryl and C6-10 aryl-C1-6 alkyl; R4 is selected from C1-6 alkyl, halogenated C1-6 alkyl, hydroxy, C1-6 hydroxyalkyl amino, amino, C1-6 alkoxy, C1-6-amino alkyl, di- C1-6-amino alkyl, hydroxyamino, alkoxy C1-6-amino, benzylamino, C2-5-alkyl heterocycle, C2-5 heteroaryl and C2-5 heteroaryl-C1-6 alkyl; X is selected from -C (= O) - and -CH2-; and m and n are independently selected from 0, 1, 2, 3, 4 and 5, with the proviso that R3 is not an optionally substituted 2,6-dioxopiperidin-3-yl.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80324206P | 2006-05-26 | 2006-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061111A1 true AR061111A1 (en) | 2008-08-06 |
Family
ID=38778884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102233A AR061111A1 (en) | 2006-05-26 | 2007-05-23 | ISOINDOL DERIVATIVES USEFUL TO TREAT PAIN, GASTROINTESTINAL DISORDERS AND CANCER |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2029535A1 (en) |
| JP (1) | JP2009538296A (en) |
| CN (1) | CN101495450A (en) |
| AR (1) | AR061111A1 (en) |
| CL (1) | CL2007001517A1 (en) |
| TW (1) | TW200806625A (en) |
| UY (1) | UY30363A1 (en) |
| WO (1) | WO2007139464A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
| BRPI0922180A2 (en) * | 2008-12-08 | 2015-12-29 | Sirtris Pharmaceuticals Inc | insoindolinone and related analogues as modulators of sirtuin |
| WO2012058133A1 (en) * | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | Isoindolinone pde10 inhibitors |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| JP6211509B2 (en) | 2012-03-02 | 2017-10-11 | 武田薬品工業株式会社 | Heterocyclic compounds and uses thereof |
| US9777005B2 (en) | 2012-11-19 | 2017-10-03 | Takeda Pharmaceutical Company Limited | Bicyclic heterocyclic compound containing a substituted pyrrole ring |
| PL3134386T3 (en) | 2014-04-23 | 2020-11-16 | Takeda Pharmaceutical Company Limited | Isoindoline-1-one derivatives as cholinergic muscarinic m1 receptor positive alloesteric modulator activity for the treatment of alzheimers disease |
| EP3144308B1 (en) | 2014-05-16 | 2020-06-24 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| KR101846475B1 (en) | 2015-04-27 | 2018-04-09 | 주식회사 녹십자 | COMPOUNDS AS TNIK, IKKε AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME |
| US20240076291A1 (en) * | 2020-11-24 | 2024-03-07 | Merck Sharp & Dohme Llc | Modified isoindolinones as glucosylceramide synthase inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| DE10134482A1 (en) * | 2001-07-16 | 2003-01-30 | Bayer Ag | Substituted isoindoles and their use |
| DE10137163A1 (en) * | 2001-07-30 | 2003-02-13 | Bayer Ag | New thiophenecarboxamido-substituted isoindole derivatives, useful as Factor XIa inhibitors for treatment or prophylaxis of, e.g. thromboembolic diseases, atherosclerosis, arthritis, Alzheimer's disease or cancer |
| US7405237B2 (en) * | 2004-07-28 | 2008-07-29 | Celgene Corporation | Isoindoline compounds and methods of their use |
| US7244759B2 (en) * | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
-
2007
- 2007-05-21 TW TW096117988A patent/TW200806625A/en unknown
- 2007-05-23 AR ARP070102233A patent/AR061111A1/en not_active Application Discontinuation
- 2007-05-24 WO PCT/SE2007/000503 patent/WO2007139464A1/en not_active Ceased
- 2007-05-24 UY UY30363A patent/UY30363A1/en not_active Application Discontinuation
- 2007-05-24 EP EP07748167A patent/EP2029535A1/en not_active Withdrawn
- 2007-05-24 JP JP2009511980A patent/JP2009538296A/en active Pending
- 2007-05-24 CN CNA2007800284618A patent/CN101495450A/en active Pending
- 2007-05-25 CL CL2007001517A patent/CL2007001517A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101495450A (en) | 2009-07-29 |
| CL2007001517A1 (en) | 2008-01-25 |
| EP2029535A1 (en) | 2009-03-04 |
| WO2007139464A1 (en) | 2007-12-06 |
| UY30363A1 (en) | 2008-01-02 |
| TW200806625A (en) | 2008-02-01 |
| JP2009538296A (en) | 2009-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061111A1 (en) | ISOINDOL DERIVATIVES USEFUL TO TREAT PAIN, GASTROINTESTINAL DISORDERS AND CANCER | |
| AR063602A1 (en) | DERIVATIVES OF SPIROINDOLINONE, PHARMACEUTICAL FORMULATIONS THAT CONTAIN THEM AND THEIR USE IN THE OBTAINING OF A MEDICINAL PRODUCT FOR THE TREATMENT OF ONCOLOGICAL DISORDERS. | |
| AR059957A1 (en) | DERIVATIVES OF SPIROINDOLINONE, METHODS FOR THEIR PREPARATION, A PHARMACEUTICAL COMPOSITION CONTAINING THEM AND THEIR USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF CANCER. | |
| PE20220567A1 (en) | NEW PIPERIDINIL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| PE20142456A1 (en) | OXAZOLIDIN-2-ONA COMPOUNDS AND USES OF THE SAME AS INHIBITORS OF PI3Ks | |
| AR072906A1 (en) | MODIFIED NUCLEOSIDS USEFUL AS ANTIVIRAL | |
| HUP0200859A2 (en) | Cyclo-alkyl substituted benzimidazoles, pharmaceutical compositions containing them, their preparation and their use | |
| AR081426A1 (en) | PIRAZOL DERIVATIVES INHIBITORS OF THE SIGMA RECEIVER | |
| AR061369A1 (en) | PIRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM | |
| AR066020A1 (en) | DERIVATIVES OF IMIDAZOLIDIN-2, 4-DIONA, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF PARP-1. | |
| AR086100A1 (en) | CHROMENONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| AR049578A1 (en) | HYDANTOIN DERIVATIVES, OBTAINING PROCESSES AND PHARMACEUTICAL COMPOSITIONS | |
| UY26048A1 (en) | DERIVATIVES OF PIRIDOPIRANOACEPINAS, ITS PREPARATION AND ITS THERAPEUTIC APPLICATION | |
| AR069607A1 (en) | INHIBITORS OF THE ESTEAROIL-COA DESATURASA | |
| UY29393A1 (en) | NEW DERIVATIVES OF AMIDAS, ACCEPTABLE PHARMACEUTICAL SALTS, COMPOSITIONS THAT CONTAIN THEM, PREPARATION PROCEDURES AND APPLICATIONS. | |
| UY29312A1 (en) | PIPERAZIN-1-CARBOXAMIDAS N, 4, SUBSTITUTES AND THEIR DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURES AND APPLICATIONS | |
| CL2011001050A1 (en) | Compound 2-methyl-1- (phenylsulfonyl) -4- (piperazin-1-yl) -1h-benzimidazole, which is a 5-hydroxytryptamine-6 ligand; its pharmaceutical composition; 5-ht6 activity modulator; its use in the treatment of disorders of the central nervous system, such as psychosis, anxiety, depression, epilepsy, among others. | |
| AR046793A1 (en) | DERIVADOS DE PIRAZOL, ANTAGONISTS OF THE RECEIVER OF OREXINA | |
| UY27803A1 (en) | DERIVATIVES OF BENZOXAZINE AND USES OF THE SAME. | |
| ECSP088257A (en) | AMIDA DERIVATIVES | |
| AR061185A1 (en) | HETEROCICLICAL COMPOUNDS AS INHIBITORS OF HSP90. PHARMACEUTICAL COMPOSITIONS. | |
| AR049276A1 (en) | OPIOOD CARBOXAMID COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| AR054790A1 (en) | METHODS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | |
| AR064488A1 (en) | DERIVATIVES OF 4- (1-AMINO-ETIL) -CICLOHEXILAMINE, A PHARMACEUTICAL COMPOSITION CONTAINING IT AND THE USE OF THEM FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF A BACTERIAL INFECTION | |
| AR072880A1 (en) | NITROGEN DERIVATIVES OF PANCRATISTATINE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |